CY1106590T1 - Νεα διεργασια για τη συνθεση 5-(4-φθοροφαινυλο)-1-[2-((2r,4r)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλο)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1h-πυρρολο-3-καρβοξυλικου οξεος φαινυλαμιδης - Google Patents

Νεα διεργασια για τη συνθεση 5-(4-φθοροφαινυλο)-1-[2-((2r,4r)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλο)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1h-πυρρολο-3-καρβοξυλικου οξεος φαινυλαμιδης

Info

Publication number
CY1106590T1
CY1106590T1 CY20071100653T CY071100653T CY1106590T1 CY 1106590 T1 CY1106590 T1 CY 1106590T1 CY 20071100653 T CY20071100653 T CY 20071100653T CY 071100653 T CY071100653 T CY 071100653T CY 1106590 T1 CY1106590 T1 CY 1106590T1
Authority
CY
Cyprus
Prior art keywords
pyran
fluorophenyl
pyrrole
tetrahydro
oxo
Prior art date
Application number
CY20071100653T
Other languages
English (en)
Inventor
Donald Eugene Butler
Randall Lee Dejong
Jade Douglas Nelson
Michael Gerard Pamment
Timothy Lee Stuk
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of CY1106590T1 publication Critical patent/CY1106590T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)

Abstract

Μία βελτιωμένη διεργασία για τη παρασκευή 5-(4-φθοροφαινυλο)-1-[2-((2R,4R)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλ)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1Η-πυρρολο-3-καρβοξυλικού οξέως φαινυλαμίδης μέσω μιας νέας σύνθεσης περιγράφεται όπου ο κυανοξικός μεθυλεστέρας μετατρέπεται σε οκτώ χειρισμούς ή λιγότερους στο επιθυμητό προϊόν, όπως επίσης άλλα πολύτιμα ενδιάμεσα χρησιμοποιούμενα στη διεργασία.
CY20071100653T 2001-01-09 2007-05-14 Νεα διεργασια για τη συνθεση 5-(4-φθοροφαινυλο)-1-[2-((2r,4r)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλο)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1h-πυρρολο-3-καρβοξυλικου οξεος φαινυλαμιδης CY1106590T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09
PCT/IB2001/002729 WO2002055519A2 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide

Publications (1)

Publication Number Publication Date
CY1106590T1 true CY1106590T1 (el) 2012-01-25

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100653T CY1106590T1 (el) 2001-01-09 2007-05-14 Νεα διεργασια για τη συνθεση 5-(4-φθοροφαινυλο)-1-[2-((2r,4r)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλο)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1h-πυρρολο-3-καρβοξυλικου οξεος φαινυλαμιδης

Country Status (25)

Country Link
US (7) US6476235B2 (el)
EP (1) EP1353917B1 (el)
JP (2) JP4190285B2 (el)
KR (3) KR100677008B1 (el)
CN (4) CN1222521C (el)
AR (1) AR035680A1 (el)
AT (1) ATE358126T1 (el)
BR (1) BR0116739A (el)
CA (1) CA2432064C (el)
CY (1) CY1106590T1 (el)
CZ (1) CZ20031893A3 (el)
DE (1) DE60127583T2 (el)
DK (1) DK1353917T3 (el)
ES (1) ES2282200T3 (el)
HK (2) HK1060572A1 (el)
HU (1) HUP0302647A3 (el)
IL (4) IL156461A0 (el)
MX (1) MXPA03005284A (el)
PL (1) PL365283A1 (el)
PT (1) PT1353917E (el)
RU (1) RU2244714C1 (el)
TW (1) TWI293073B (el)
WO (1) WO2002055519A2 (el)
YU (1) YU49003A (el)
ZA (1) ZA200304684B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2003004456A1 (en) * 2001-07-06 2003-01-16 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
ES2287549T3 (es) * 2002-08-06 2007-12-16 Warner-Lambert Company Llc Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico.
WO2004046105A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
RS20050760A (sr) 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
ES2443994T3 (es) * 2003-06-13 2014-02-21 Boehringer Ingelheim International Gmbh Ligandos quirales para el uso en síntesis asimétricas
CN1852894A (zh) * 2003-09-17 2006-10-25 沃尼尔·朗伯有限责任公司 [R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
CN1871202A (zh) 2003-10-24 2006-11-29 隆萨股份公司 6,6,6－三卤－3,5－二氧代己酸酯的制备方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
CA2562844A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
EP3581564A1 (en) 2004-05-05 2019-12-18 Pfizer Products Inc. Diethylamine salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
SI1771455T1 (sl) * 2004-07-16 2016-09-30 Lek Pharmaceuticals D.D. Oksidacijski razgradni produkti atorvastatin kalcija
WO2006011041A2 (en) * 2004-07-20 2006-02-02 Warner-Lambert Company Llc Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
KR101155288B1 (ko) * 2004-07-30 2012-07-02 엑셀리시스, 인코포레이티드 의약제로서의 피롤 유도체
WO2006046109A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006059224A1 (en) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
WO2006097909A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (en) * 2005-03-24 2006-09-27 ratiopharm GmbH Process for preparing C5 products and their use for Atorvastatin synthesis
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
CA2652412A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo METHODS OF MAKING OPTICALLY PURE BETA-LACTONES FROM ALDEHYDES AND COMPOSITIONS OBTAINED THEREFROM
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
US20130178636A1 (en) 2010-09-16 2013-07-11 Dsm Sinochem Pharmaceuticals Netherlands B.V. Esters of hexanoic acids as intermediates for the preparation of atorvastatin
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
EP2726456A1 (en) 2011-07-01 2014-05-07 DSM Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
JP6970105B2 (ja) * 2016-02-11 2021-11-24 スティヒティング カソリーケ ユニベルシタイトStichting Katholieke Universiteit 心血管疾患の治療のための新規クラスの化合物
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO1997003959A1 (en) 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AU2077897A (en) * 1996-04-10 1997-10-29 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2176756T3 (es) 1996-07-29 2002-12-01 Warner Lambert Co Proceso perfeccionado para la sintesis de los esteres protegidos del acido (s)-3,4-dihidroxibutirico.
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
KR20030065594A (ko) 2003-08-06
US6545153B1 (en) 2003-04-08
IL189358A0 (en) 2008-06-05
US7399773B2 (en) 2008-07-15
CN101024626A (zh) 2007-08-29
US7371855B2 (en) 2008-05-13
JP4190285B2 (ja) 2008-12-03
PT1353917E (pt) 2007-05-31
KR20060114395A (ko) 2006-11-06
US20030195353A1 (en) 2003-10-16
ATE358126T1 (de) 2007-04-15
WO2002055519A2 (en) 2002-07-18
WO2002055519A3 (en) 2002-09-19
IL156461A0 (en) 2004-01-04
DK1353917T3 (da) 2007-06-18
IL189357A0 (en) 2008-06-05
CA2432064A1 (en) 2002-07-18
CA2432064C (en) 2007-09-11
ZA200304684B (en) 2004-06-28
RU2244714C1 (ru) 2005-01-20
US20020133026A1 (en) 2002-09-19
US7361771B2 (en) 2008-04-22
CZ20031893A3 (cs) 2004-03-17
US20070032662A1 (en) 2007-02-08
HK1060572A1 (en) 2004-08-13
HUP0302647A3 (en) 2009-03-30
EP1353917A2 (en) 2003-10-22
JP2004520351A (ja) 2004-07-08
CN1907984A (zh) 2007-02-07
US20070032664A1 (en) 2007-02-08
YU49003A (sh) 2006-05-25
KR100833911B1 (ko) 2008-06-03
US6476235B2 (en) 2002-11-05
US6933393B2 (en) 2005-08-23
ES2282200T3 (es) 2007-10-16
CN1489587A (zh) 2004-04-14
US7183408B2 (en) 2007-02-27
IL189359A0 (en) 2008-06-05
AR035680A1 (es) 2004-06-23
DE60127583D1 (de) 2007-05-10
US20070032663A1 (en) 2007-02-08
HUP0302647A2 (hu) 2003-11-28
AU2002222430B2 (en) 2007-05-17
DE60127583T2 (de) 2007-12-06
KR20060015698A (ko) 2006-02-17
MXPA03005284A (es) 2003-09-25
CN1696129A (zh) 2005-11-16
BR0116739A (pt) 2003-09-30
TWI293073B (en) 2008-02-01
CN1222521C (zh) 2005-10-12
KR100582326B1 (ko) 2006-05-22
KR100677008B1 (ko) 2007-02-01
JP2008100989A (ja) 2008-05-01
EP1353917B1 (en) 2007-03-28
HK1084114A1 (en) 2006-07-21
CN100351252C (zh) 2007-11-28
US20050239869A1 (en) 2005-10-27
PL365283A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
CY1106590T1 (el) Νεα διεργασια για τη συνθεση 5-(4-φθοροφαινυλο)-1-[2-((2r,4r)-4-υδροξυ-6-οξο-τετραϋδρο-πυραν-2-υλο)-αιθυλο]-2-ισοπροπυλο-4-φαινυλο-1h-πυρρολο-3-καρβοξυλικου οξεος φαινυλαμιδης
NO20060044L (no) Fremgangsmate for fremstilling av substituerte 3-aryl-butyl-aminforbindelser
EA200001102A1 (ru) Способ синтеза ингибиторов сох-2 (циклооксигеназы-2)
BR0307432A (pt) Difluormetiltiazolilcarboxanilidas
ATE501126T1 (de) Verfahren zur herstellung von rosuvastatin
DE602005008402D1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
CO5261552A1 (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquino- linas 4-carboxiamino-2-sustituidas
ATE469877T1 (de) Verfahren zur dehydratisierung substituierter 4- dimethylamino-2-aryl-butan-2-ol-verbindungen und verfahren zur herstellung substituierter dimethyl-(3-aryl-butyl)-amin-verbindungen mittels heterogener katalyse
DE60123579D1 (de) Synthese von 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
EA200400487A1 (ru) Фармацевтическая композиция длительного высвобождения, содержащая метформин
DE60100238D1 (de) Synthese von 3,6-Dialkyl-5,6-Dihydro-4-Hydroxy-2H-Pyran-2-one
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
DE60228724D1 (de) Verfahren zur herstellung von beraprost und dessen salzen
NO994049L (no) Metode for aa fremstille farmasöytiske forbindelser
RS20050105A (en) Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide
BRPI0409333A (pt) processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
EA199801084A1 (ru) Спосб получения фенилгетероциклических соединений, используемых в качестве ингибиторов циклооксигеназы-2
BRPI0514313A (pt) processo para sintetizar um composto, e, composto
ATE327987T1 (de) Methylthiophencarboxanilide
ATE225363T1 (de) Synthese von morphin-6-glucuronid
EA200300771A1 (ru) Новая соль бензоилгуанидина
DE60006125D1 (de) Herstellung von 2-(2-arylmorpholin-2-yl)ethanolderivaten und zwischenprodukte
FR2751652B1 (fr) Derives du thienylcyclohexane, des procedes pour leur preparation et leur utilisation en tant que produits industriels nouveaux pour la synthese de derives thienylcyclohexyles